Fig. 1From: DEF6 expression in ovarian carcinoma correlates with poor patient survivalCytoplasmic immunoexpression of DEF6 in high-grade serous carcinoma. Case representatives show (a) negative (less than 5 %): score 0; (b) weak (5–25 %): score 1; (c) moderate (26–75 %): score 2; (d) strong (more than 75 %): score 3 of tumor cellsBack to article page